(Q38751328)

6 September 2017

title

Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy (English)

1 reference

6 September 2017

6

Peter L Choyke

1 reference

6 September 2017

Kazuhide Sato

1

1 reference

6 September 2017

Noriko Sato

2

1 reference

6 September 2017

Biying Xu

3

1 reference

6 September 2017

Yuko Nakamura

4

1 reference

6 September 2017

Tadanobu Nagaya

5

1 reference

6 September 2017

Yoshinori Hasegawa

7

1 reference

6 September 2017

Hisataka Kobayashi

8

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 August 2016

1 reference

Science Translational Medicine

6 September 2017

published in

1 reference

6 September 2017

volume

8

1 reference

6 September 2017

issue

352

1 reference

6 September 2017

page(s)

352ra110

1 reference

describes a project that uses

6 September 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC7780242/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Oncology meets immunology: the cancer-immunity cycle

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Adoptive cellular therapy: a race to the finish line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

The future of immune checkpoint therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Combination cancer immunotherapy and new immunomodulatory targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

The journey from discoveries in fundamental immunology to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Combination cancer immunotherapies tailored to the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Deciphering and reversing tumor immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Immunoengineering: how nanotechnology can enhance cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Near infrared photoimmunotherapy for lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Potent and specific antitumor effect of CEA-targeted photoimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

FOXP3+ regulatory T cells in the human immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

T-regulatory cells: key players in tumor immune escape and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Regulatory T cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Incomplete depletion and rapid regeneration of Foxp3+ regulatory T cells following anti-CD25 treatment in malaria-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

CD103 is a hallmark of tumor-infiltrating regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

IL-6 in inflammation, immunity, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF6843

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

21 January 2018

1 reference

12 December 2020

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

1 reference

12 December 2020

Effector/memory but not naive regulatory T cells are responsible for the loss of concomitant tumor immunity

1 reference

12 December 2020

Efficient Treg depletion induces T-cell infiltration and rejection of large tumors

1 reference

12 December 2020

10.1126/SCITRANSLMED.AAF6843

Identifiers

DOI

1 reference

6 September 2017

0 references

1 reference